摘要
目的:分析卡培他滨术前和术后同步放化疗对中低位直肠癌患者血清肿瘤坏死因子相关凋亡配体(TRAIL)及原癌基因(DEK)水平的影响。方法:将100例中低位直肠癌依照随机信封法分为观察组及对照组;对照组采用手术+术后放化疗方案治疗,观察组采用术前放化疗+手术+巩固化疗方案治疗;随访30个月记录两组患者生存率;治疗前及治疗结束后6个月采用ELISA法检测黏膜组织中TRAIL及DEK水平。结果:治疗后观察组黏膜组织中TRAIL水平显著高于对照组(P<0.05),治疗后观察组黏膜组织中DEK水平显著低于对照组(P<0.05);观察组患者随访生存期明显优于对照组,且差异有统计学意义(P<0.05)。结论:采用卡培他滨术前和术后同步放化疗对中低位直肠癌患者治疗后可有效升高患者手术病灶部位TRAIL水平并降低DEK水平,具有较高的临床应用价值。
Objective:To analyze the effect of preoperative and postoperative concurrent chemoradiotherapy on serum TRAIL and DEK levels in patients with capecitabine.Methods:100 cases of middle and low rectal cancer were divided into observation group and control group according to random envelope method;the control group was treated with surgery plus postoperative chemotherapy and radiotherapy, the observation group was treated with preoperative chemotherapy + surgery + consolidation chemotherapy;30 cases were followed up. The survival rates of the two groups were recorded monthly, and the levels of TRAIL and DEK in the mucosa were detected by ELISA before and 6 months after treatment.Results:The level of TRAIL in the mucosa of the observation group was significantly higher than that of the control group ( P <0.05);the level of DEK in the mucosa of the observation group was significantly lower than that of the control group ( P <0.05);the survival time of the observation group was significantly better than that of the control group, and the difference was statistically significant( P <0.05).Conclusions:Preoperative and postoperative concurrent chemoradiotherapy with capecitabine can effectively elevate TRAIL level and reduce DEK level in patients with middle and low rectal cancer.
作者
王美玲
卞邦健
WANG Meiling;BIAN Bangjian(Shanghai Jiao Tong University School of Medicine Shanghai 201999)
出处
《陕西医学杂志》
CAS
2019年第4期502-504,共3页
Shaanxi Medical Journal
关键词
中低位直肠癌
卡培他滨
术前和术后同步放化疗
TRAIL
DEK
影响
Central and low rectal cancer
Capecitabine
Preoperative and postoperative concurrent chemoradiotherapy
TRAIL
DEK
Influences
